Trade Allogene Therapeutics, Inc. - ALLO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.03 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.55 |
| Open | 1.54 |
| 1-Year Change | -86.77% |
| Day's Range | 1.51 - 1.56 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 1.55 | -0.01 | -0.64% | 1.56 | 1.60 | 1.53 |
| Apr 23, 2025 | 1.59 | -0.06 | -3.64% | 1.65 | 1.73 | 1.59 |
| Apr 22, 2025 | 1.56 | 0.14 | 9.86% | 1.42 | 1.57 | 1.42 |
| Apr 21, 2025 | 1.41 | 0.01 | 0.71% | 1.40 | 1.47 | 1.38 |
| Apr 17, 2025 | 1.44 | 0.06 | 4.35% | 1.38 | 1.46 | 1.36 |
| Apr 16, 2025 | 1.39 | -0.03 | -2.11% | 1.42 | 1.42 | 1.38 |
| Apr 15, 2025 | 1.45 | 0.04 | 2.84% | 1.41 | 1.51 | 1.39 |
| Apr 14, 2025 | 1.41 | -0.04 | -2.76% | 1.45 | 1.47 | 1.37 |
| Apr 11, 2025 | 1.43 | 0.11 | 8.33% | 1.32 | 1.44 | 1.31 |
| Apr 10, 2025 | 1.36 | 0.00 | 0.00% | 1.36 | 1.43 | 1.35 |
| Apr 9, 2025 | 1.41 | 0.09 | 6.82% | 1.32 | 1.47 | 1.22 |
| Apr 8, 2025 | 1.36 | -0.15 | -9.93% | 1.51 | 1.56 | 1.32 |
| Apr 7, 2025 | 1.42 | 0.03 | 2.16% | 1.39 | 1.49 | 1.35 |
| Apr 4, 2025 | 1.43 | 0.11 | 8.33% | 1.32 | 1.44 | 1.31 |
| Apr 3, 2025 | 1.37 | 0.02 | 1.48% | 1.35 | 1.43 | 1.34 |
| Apr 2, 2025 | 1.43 | 0.14 | 10.85% | 1.29 | 1.45 | 1.29 |
| Apr 1, 2025 | 1.36 | -0.07 | -4.90% | 1.43 | 1.43 | 1.29 |
| Mar 31, 2025 | 1.44 | -0.04 | -2.70% | 1.48 | 1.48 | 1.37 |
| Mar 28, 2025 | 1.54 | -0.08 | -4.94% | 1.62 | 1.67 | 1.50 |
| Mar 27, 2025 | 1.54 | 0.00 | 0.00% | 1.54 | 1.56 | 1.48 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com